Anti-inflammatory effects of escin are correlated with the glucocorticoid receptor/NF-κB signaling pathway, but not the COX/PGF2α signaling pathway

Experimental and Therapeutic Medicine

Volumn 6, Issue 2, 2013, Pages 419-422

  Wang, Hongsheng ^a   Zhang, Leiming ^a   Jiang, Na ^a   Wang, Zhenhua ^a   Chong, Yating ^a   Fu, Fenghua ^a  

^a YANTAI UNIVERSITY   (China)

Author keywords

Escin; Glucocorticoid; Inflammation; Nuclear factor B; Prostaglandin F2

Indexed keywords

DICLOFENAC; ESCIN; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN F2 ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY PERMEABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PAW EDEMA; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

EID: 84879643959     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1128     Document Type: Article

References (20)

1. Fu F, Hou Y, Jiang W, Wang R and Liu K: Escin: inhibiting inflammation and promoting gastrointestinal transit to attenuate formation of postoperative adhesions. World J Surg 29: 1614-1620, 2005.
2. Zhang L, Fu F, Zhang X, Zhu M, Wang T and Fan H: Escin attenuates cognitive deficits and hippocampal injury after transient global cerebral ischemia in mice via regulating certain inflammatory genes. Neurochem Int 57: 119-127, 2010.
3. Xin W, Zhang L, Fan H, Jiang N, Wang T and Fu F: Escin attenuates acute lung injury induced by endotoxin in mice. Eur J Pharm Sci 42: 73-80, 2011.
4. Jiang N, Xin W, Wang T, Zhang L, Fan H, Du Y, Li C and Fu F: Protective effect of aescin from the seeds of Aesculus hippocastanum on liver injury induced by endotoxin in mice. Phytomedicine 18: 1276-1284, 2011.
5. Zhang L, Wang H, Fan H, Wang T, Jiang N, Yu P and Fu F: The potent anti-infl ammatory agent escin does not increase corticosterone secretion and immune cell apoptosis in mice. Fitoterapia 82: 861-867, 2011.
6. Rhen T and Cidlowski JA: Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353: 1711-1723, 2005.
7. Wang YW, Wang SJ, Zhou YN, Pan SH and Sun B: Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol 138: 785-797, 2012.
8. Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S and Aggarwal BB: Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol 77: 818-827, 2010.
9. Williams PB and Joyner JH: Response of peripheral collateral arteries in the dog to prostaglandins E1, E2, F2 alpha, and I2 (prostacyclin). J Cardiovasc Pharmacol 4: 784-790, 1982.
10. Emerson TE Jr, Jelks GW, Daugherty RM Jr and Hodgman RE: Effects of prostaglandin E1 and F2 alpha on venous return and other parameters in the dog. Am J Physiol 220: 243-249, 1971.
11. Uski TK, Andersson KE, Brandt L and Ljunggren B: Characterization of the prostanoid receptors and of the contractile effects of prostaglandin F2 alpha in human pial arteries. Acta Physiol Scand 121: 369-378, 1984.
12. Amann-Vesti BR, Gitzelmann G, Koppensteiner R and Franzeck UK: Isoprostane 8-epi-prostaglandin F2 alpha decreases lymph capillary pressure in patients with primary lymphedema. J Vasc Res 40: 77-82, 2003.
13. Sinzinger H, Oguogho A and Kaliman J: Isoprostane 8-epi-prostaglandin F2 alpha is a potent contractor of human peripheral lymphatics. Lymphology 30: 155-159, 1997.
14. Longiave D, Omini C, Nicosia S and Berti F: The mode of action of aescin on isolated veins: relationship with PGF2 alpha. Pharmacol Res Commun 10: 145-152, 1978.
15. Berti F, Omini C and Longiave D: The mode of action of aescin and the release of prostaglandins. Prostaglandins 14: 241-249, 1977.
16. Carrasco OF and Vidrio H: Endothelium protectant and contractile effects of the antivaricose principle escin in rat aorta. Vascul Pharmacol 47: 68-73, 2007.
17. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, et al: International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 58: 782-797, 2006.
18. Mckay LI and Cidlowski JA: Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocrine Rev 20: 435-459, 1999.
19. Ku EC, Wasvary JM and Cash WD: Diclofenac sodium (GP 45840, Voltaren), a potent inhibitor of prostaglandin synthetase. Biochem Pharmacol 24: 641-643, 1975.
20. Ku EC, Kothari H, Lee W, Kimble EF and Liauw LH: Effects of diclofenac sodium on arachidonic acid metabolism. Agents Actions Suppl 17: 189-193, 1985.